magnolol

Magnolol

Magnolol is a bioactive polyphenolic neolignan derived primarily from the bark of Magnolia officinalis Rehd. et Wils. (family Magnoliaceae). It has been documented in traditional Chinese and Japanese medicine for over two millennia and has accumulated a substantial body of preclinical research demonstrating a wide range of pharmacological activities. As of the mid-2020s, human clinical evidence for isolated magnolol remains limited, and most pharmacological characterization derives from cell-based and animal studies.

1. Identity, Chemistry, and Natural Sources

1.1 Chemical Identity

Magnolol is a natural bioactive compound isolated from the bark of Magnolia officinalis, classified as a neolignan — a class of compounds characterized by the presence of two phenylpropanoid monomers within their molecular framework. Chemically, it is designated 5,5′-diallyl-2,2′-dihydroxybiphenyl and is a structural isomer of honokiol; both are isolated from the traditional Chinese herbal medicine Magnolia officinalis.

Magnolol carries CAS number 528-43-8 and has the molecular formula C₁₈H₁₈O₂ with a molecular weight of 266.3. They are classified as neolignans, a class of compounds characterized by the presence of two phenylpropanoid monomers within their molecular framework. In the solid state, magnolol shows a high degree of crystallinity, with a melting point around 102 °C. Magnolol showed a lower solubility than honokiol at acidic pH values, but a higher solubility at alkaline pH values; partition coefficients were similar and relatively high for both compounds (log P_o/w ≈ 4.5), indicating their lipophilic nature.

The low bioavailability of magnolol has been attributed to its very low water solubility. The use of magnolol can be limited due to chemical instability; its stability can be affected by hydrolytic and oxidizing conditions due to its biphenolic structure.

1.2 Natural Sources and Distribution

Magnolol is an organic compound classified as a lignan. It is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis) and in M. grandiflora. Magnolol is a bioactive neolignan extracted from the root and stem bark of different Chinese herbal Magnolia trees. Magnolol is the bioactive constituent of Magnolia Cortex, the bark of Magnolia officinalis, Rehd. et Wils., Magnoliaceae, or of M. obovata, Thunb., called wakoboku in Japanese medicine.

Magnoliae officinalis cortex was first recorded in the "Shennong Herbal Classic" (Qin and Han Dynasty, around 221 B.C. to 220 A.D.), and is the dry bark, root bark, and branch bark of Magnolia officinalis Rehd. et Wils. Magnolol is one of the primary active components of Magnoliae officinalis cortex, which has been widely used in traditional Chinese and Japanese herbal medicine and possesses a wide range of pharmacological activities.

1.3 Common Forms and Preparations

Magnolol is commercially available and studied in several forms:

• Standardized bark extract (magnolia bark extract, MBE): Dried or concentrated extracts of the stem, root, and branch bark of Magnolia officinalis, standardized to a defined percentage of magnolol and honokiol combined. The source information on Magnoliae officinalis cortex is provided by the 2020 edition of the Chinese Pharmacopoeia.
• Isolated pure magnolol: Magnolol is commercially available as a pure substance isolated from magnolia extracts.
• Traditional decoctions: Magnolia officinalis cortex is the main component of Chinese medicine formulae Banxia Houpo decoction, Huoxiang Zhengqi powder, and Japanese formula Saibokuto, among others.
• Novel delivery systems: Magnolol exemplifies a typical case study of type IV molecules within the biopharmaceutical classification system, characterized by low solubility and low absorption, resulting in very low bioavailability following oral administration. Drug carrier systems such as vectorization platforms enhance the stability of the medication, improve pharmacokinetic parameters, and consequently increase bioavailability. Investigational preparations include solid dispersions, mixed micelle systems, nanoparticles, and lecithin-based polymeric micelles.

2. Traditional and Historical Use

2.1 Traditional Chinese Medicine (TCM)

Magnoliae officinalis Cortex (Houpo) is the dried stem bark, root bark, or branch bark of Magnolia officinalis Rehd. et Wils. (Magnoliaceae). It has been used as a TCM for more than 2,000 years for the treatment of epigastric stuffiness, vomiting and diarrhea, abdominal distention and constipation, cough and dyspnea.

Both magnolol and honokiol are isolated from the stem bark of a traditional Chinese herbal medicine Magnolia officinalis, which has been used for management of nervous disturbance, abdominal distention or disorders, gastrointestinal food stagnancy, and coughing and dyspnea.

Historically, in traditional Chinese medicine, magnolol and honokiol were utilized for the management of thrombotic stroke, gastrointestinal disturbances, anxiety, nervous system disorders, and allergic and inflammatory diseases, as well as malignant neoplasms.

Magnolia officinalis is a flowering herb that has been used in traditional Chinese medicine to treat anxiety, depression, stress, nervousness, and sleep-related problems. It is also used to regulate gastrointestinal motility and is found in herbal formulas such as Ma Zi Ren Wan.

2.2 Japanese Kampo Medicine

Honokiol and magnolol were initially described as components of the genus Magnolia, which are components of Chinese (Kampo) herbs, including houpo and saiboku-tu(o). In Japanese Kampo medicine, magnolol is sourced from the bark of M. obovata, Thunb., called wakoboku.

Magnolia officinalis Cortex, as a classic traditional herbal drug, is tracked back approximately 2,000 years in China, Japan, South Korea, and other Asian countries. Magnolia officinalis Cortex is the main component of Chinese medicine formulae Banxia Houpo decoction, Huoxiang Zhengqi powder, and the Japanese formula Saibokuto.

2.3 Korean Traditional Medicine

Magnolia has been commonly included in two traditional Korean herbal medicines — Gwakhyangjeonggi-san and KMP6 — for atopic dermatitis treatment, and magnolol is the major constituent of Magnolia.

2.4 Traditional Therapeutic Applications

The bark of Magnolia officinalis is reportedly used as an antibacterial, antiseptic, antispasmodic, aphrodisiac, appetizer, digestive, diuretic, emmenagogue, expectorant, ophthalmic, stomachic, and tonic. These traditional applications span the gastrointestinal, respiratory, and nervous systems, and reflect a broad-spectrum use consistent with the compound's multifunctional pharmacological profile now being characterized scientifically.

3. Key Constituents, Co-Occurring Compounds, and Structural Relationships

Magnolol, honokiol, 4-O-methylhonokiol, obovatol, and other neolignans found in the bark of the Magnolia tree are some of the principal compounds that confer medicinal qualities to the plant.

Magnolol and its structural isomer honokiol share the same molecular formula but differ in the position of their hydroxyl groups. They are classified as neolignans. These two structural isomers possess two hydroxyl moieties, the precise spatial arrangement of which critically dictates their biological properties and modulates their stability. Through DPPH and SOD activity assays, both magnolol and honokiol have antioxidant activities; however, honokiol has relatively stronger antioxidant activities than magnolol.

The potent antioxidant activities of magnolol and honokiol are thought to be the contribution of hydroxyl and allylic groups on a biphenolic moiety. The hydroxyl group on the biphenolic moiety contributes to magnolol/honokiol activity against reactive oxygen species, inhibiting cell proliferation and conferring antimicrobial activity.

4. Mechanisms of Action

Magnolol has shown a wide spectrum of beneficial activities, including anti-inflammation, antimicroorganism, antioxidation, antiangiogenesis, anticancer, neuroprotection, cardiovascular protection, and lipolysis activities. The molecular basis of these effects involves multiple, often overlapping signaling pathways.

4.1 Anti-Inflammatory Pathways

The chemical structure of magnolol allows it to interact with a variety of molecular targets, primarily influencing signaling pathways that regulate inflammation and oxidative stress. One significant mechanism involves its ability to modulate the activity of transcription factors such as NF-κB, which plays a critical role in the inflammatory response. By inhibiting NF-κB activation, magnolol can reduce the expression of pro-inflammatory cytokines and mediators, thereby modulating inflammatory processes.

Magnolol had dose-dependent effects on enhancement of phagocytosis ability and significantly inhibited NO production at concentration ranges from 10 to 40 μM. Furthermore, magnolol significantly reduced the gene expression and protein release of IL-1β and TNF-α. The p-ERK1/2 in the MAPK signaling pathway was not significantly affected by magnolol, whereas p-JNK and p-P38 were down-regulated. Magnolol also inhibited the expression of p-IκBα and p-P65 of NF-κB signaling pathways.

Inflammation is generally characterized by overexpression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and excessive synthesis of nitric oxide (NO) and prostaglandins. MAPK and NF-κB are the most crucial signaling pathways in the inflammatory process. Magnolol can exhibit anti-inflammatory activity by inhibiting the production of inflammatory enzymes/cytokines and activation of NF-κB and leukocyte.

4.2 Antioxidant Mechanisms

The ability of magnolol to inhibit oxidative stress was first demonstrated in vitro. Rate constants for competition reactions between hydroxyl radicals and biphenyl compounds including magnolol were estimated. It is thought that the chemical mechanism by which magnolol may function involves a peroxide intermediate followed by a phenolic hydroxyl group attacking the peroxide carbon chain, yielding a pentose or hexose ring and water.

It has been found that magnolol inhibited oxidative stress through up-regulating the activities of HO-1, Nrf2, and PPARγ, and the phosphorylation of PI3K and AKT.

4.3 GABAergic Modulation

Magnolol acts on GABA_A receptors and functions as an allosteric modulator. Magnolol, an active ingredient of the bark of Magnolia officinalis, has been reported to exert potent anti-epileptic effects via the GABA_A receptor. The receptor also mediates sleep in humans and animals. Magnolol participates in neurotransmitter modulation through enhancement of GABAergic transmission, with implications for anxiety and epilepsy disorders.

4.4 PPARγ Agonism

Magnolol binds in a dimeric form to PPARγ, acting as an agonist of this nuclear receptor. With regard to diabetes and obesity, the benefit from magnolol results in part from its being a strong agonist of peroxisome proliferator-activated receptor gamma (PPARγ). Magnolol functions as a PPARγ agonist through direct binding to the PPARγ ligand binding domain.

4.5 Cancer-Related Signaling Pathways

The plausible molecular mechanisms liable for the anti-cancer potential of magnolol are reduced cell proliferation or cell cytotoxicity, induction of apoptosis, accumulation of reactive oxygen species (ROS), induction of autophagy, and activation/inactivation of various cellular signaling pathways. Magnolol acts via onset of the tumor suppressor p53 pathway and inhibition/downregulation of tumor progression NF-κB, Wnt/β-catenin, PI3K-AKT, and MAPK/ERK pathways.

4.6 Blood-Brain Barrier Penetration

As main active substances derived from Magnolia officinalis, their pharmacological activities have attracted extensive attention. It is reported that both magnolol and honokiol can cross the blood-brain barrier (BBB) and exert neuroprotective effects through a variety of mechanisms. This suggests that these two ingredients can be used as effective therapeutic compounds to treat a wide range of neurological diseases.

4.7 α-Glucosidase Inhibition

Magnolol and luteolin were evaluated on the α-glucosidase target, involved in the control of hyperglycemia and related induced damage. Magnolol is a polyphenol belonging to the class of lignans, detected mainly in Magnolia officinalis. These were responsible for a reversible inhibition of the enzyme, and this is the first evidence for magnolol of its reversible interaction with α-glucosidase.

4.8 PTP1B Inhibition

PTP1B plays the role of a negative regulator of the insulin signaling pathway; therefore, the potential use of PTP1B inhibitors may result in improvement of some diabetic parameters. In vitro studies showed that magnolol is an inhibitor of PTP1B, which inhibits the expression of this phosphatase in a dose-dependent manner. Based on the Lineweaver–Burk plot and molecular docking, magnolol was determined to be a non-competitive PTP1B inhibitor. More importantly, it exhibited enzymatic selectivity for PTP and promoted cellular activity in the insulin signaling pathway.

5. Scientific Evidence by Health Area

The large majority of the evidence base for magnolol is preclinical (cell cultures and animal models). The following sections characterize both the preclinical data and the limited human/clinical evidence available, with explicit notation of evidence strength.

5.1 Neurological and Psychiatric Effects

5.1.1 Anxiolytic and Sedative/Sleep-Promoting Effects

Evidence level: Preclinical (animal models); human clinical evidence is limited and largely derives from combination magnolia bark extracts rather than isolated magnolol.

Magnolol administered intraperitoneally at a dose of 5 or 25 mg/kg significantly shortened sleep latency and increased the amount of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep for 3 hours after administration, with an increase in the number of NREM and REM sleep episodes. Immunohistochemical study showed that magnolol increased c-Fos expression in neurons of the ventrolateral preoptic area, a sleep center in the anterior hypothalamus, and decreased c-Fos expression in the arousal tuberomammillary nucleus. The sleep-promoting effects and changes in c-Fos induced by magnolol were reversed by flumazenil, an antagonist at the benzodiazepine site of the GABA_A receptor. These results are from murine models only.

Honokiol and magnolol have shown anxiolytic effects associated with modulation of GABAergic neurotransmission; and when combined in a prescription with other Chinese herbal medicines (Banxia Houpu), M. officinalis was antidepressant in vivo.

5.1.2 Neuroprotection and Alzheimer's Disease

Evidence level: Preclinical only.

Magnolol has shown the capacity to scavenge reactive oxygen species and block pro-inflammatory pathways such as MAPK and NF-κβ, modulate GABAergic signaling, upregulate brain-derived neurotrophic factor, and inhibit amyloid-beta aggregation — all of which are critical pathways in the pathophysiology of neurological disorders.

Magnolol and honokiol treatment was demonstrated to increase the release of hippocampal acetylcholine in in vivo studies and to inhibit age-related memory loss in senescence-accelerated-prone 8 (SAMP8) mice. In an in vivo study, Lee et al. (2012) demonstrated that oral application of M. officinalis ethanol extract at 2.5, 5, or 10 mg/kg doses improved Aβ1–42-induced memory impairments, inhibited Aβ1–42 accumulation, apoptosis-related neuronal cell death, and expression of BACE1 in human APP 695-expressing Tg2576 mice.

Magnolol exhibited anti-Alzheimer's disease, antiepileptic, and neuroprotective activities by acting on PPARγ targets, GABA_A/benzodiazepine receptor complexes, NF-κB, JNK/mitochondrial/caspase, and PI3K/MEK/ERK/Akt/FoxO1 pathways, alleviating inflammation, promoting microglia phagocytosis and Aβ degradation, reducing seizure mortality, prolonging seizure time, and inhibiting apoptosis. All of this evidence remains in cell and animal models.

5.1.3 Depression

Evidence level: Primarily preclinical; some human evidence for combination formulas.

Magnolol and honokiol have been reviewed for their mechanisms in combating diseases such as cerebral ischemia, neuroinflammation, Alzheimer's disease, and brain tumors, as well as psychiatric disorders such as anxiety and depression. Although magnolol and honokiol have these pharmacological effects, their clinical potential remains untapped. More research is needed to improve bioavailability of magnolol and honokiol and perform experiments to examine their therapeutic potential.

5.2 Anti-Inflammatory Effects

Evidence level: Robust preclinical; no controlled human trials for isolated magnolol.

The inhibitory effect of magnolol on the expression of pro-inflammatory cytokines and enzymes in IL-1β-stimulated fibroblast-like synoviocytes (FLS) was examined. Magnolol was found to reduce IL-1β-induced IL-6, COX-2, MMP-1, and MMP-13 expression, and these effects correlated with its inhibition of NF-κB and MAPK activation. Furthermore, studies using an adjuvant-induced arthritis rat model showed that magnolol inhibited the development of arthritis, suggesting its potential as a therapeutic agent in inflammatory arthritis.

Magnolol attenuates the expression of TNFα, IL-1β, and IL-12 induced by dextran sulphate sodium (DSS) through downregulation of NF-κB and upregulation of PPARγ expression in ulcerative colitis mice. In addition, magnolol significantly upregulates the expression of ZO-1 and occludin in DSS-induced ulcerative colitis mice.

The production of interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) induced by P. acnes in THP-1 cells, a human monocytic cell line, was reduced by magnolol (10 μM: 42.7% inhibition for IL-8; 20.3% inhibition for TNF-alpha). Cyclooxygenase-2 (COX-2) activity was also suppressed (15 μM magnolol: 45.8% inhibition). These are in vitro findings.

5.3 Gastrointestinal Effects

Evidence level: Preclinical and traditional use; limited human clinical data from combination formula studies.

In the gastrointestinal system, magnolol demonstrated anti-gastric ulcer, anti-esophageal obstruction, hepatoprotective, and anti-diarrhea effects.

Magnolol exhibits protective activity against DSS-induced ulcerative colitis mice, with a possible molecular mechanism involving augmentation of aryl hydrocarbon receptor (AHR) activation through enhancement of tryptophan metabolites production, which significantly suppresses colonic inflammation. In 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced rat colitis, magnolol reduces the activity of colonic myeloperoxidase, the levels of pro-inflammatory cytokines, and the mRNA expression of toll-like receptor 4 (TLR4).

The loss of body weight and the shorter length of colon were significantly improved in DSS-treated colitis C57BL/6 mice after the administration of magnolol. The cytokines of pro-inflammatory factors TNF-α, IL-6, and IL-1β attenuated significantly in a concentration-dependent manner. The histopathological manifestations of 5–20 mg/kg after the treatment of magnolol were markedly improved in the DSS-treated mice.

5.4 Cardiovascular Effects

Evidence level: Preclinical; no controlled human trials for isolated magnolol.

Magnolol has been known to be a cardiovascular protector since 1994. The multiplex mechanisms of magnolol on cardiovascular protection depend on cell types and dosages. Magnolol under low and moderate dosage possesses the ability to protect the heart from ischemic/reperfusion injury, reduces atherosclerotic change, protects endothelial cells against apoptosis, and inhibits neutrophil-endothelial adhesion.

The moderate to high concentration of magnolol mainly acts on smooth muscle cells and platelets. Magnolol induces apoptosis in vascular smooth muscle cells at moderate concentration and inhibits proliferation at moderate and high concentration. High concentration of magnolol also abrogates platelet activation, aggregation, and thrombus formation.

Magnolol has been demonstrated to restore insulin-mediated activity of Akt and eNOS and of vasodilatation of the aorta, upregulate the expression of PPARγ, and downregulate the expression of TRB3 in spontaneous hypertensive rats (SHR) and cultured human umbilical vein endothelial cells (HUVECs).

Oral intake of magnolol to reach the therapeutic level for cardiovascular protection is considered applicable, making magnolol an agent of potential for preventing cardiovascular diseases in high-risk patients. This conclusion is based on preclinical data.

5.5 Metabolic and Antidiabetic Effects

Evidence level: Preclinical; combination formula studies include some human data, but no human trials with isolated magnolol.

In preclinical experiments, magnolol was found to have anti-oxidative, anti-inflammatory, anti-tumorigenic, anti-diabetic, anti-microbial, anti-neurodegenerative, and anti-depressant properties.

Preclinical results suggest that magnolol exerts protective effects against steatosis and hyperlipidemia, with the underlying mechanism closely associated with AKT/AMPK/PPARα activation and MAPK/NF-κB/SREBP-1c inhibition.

After careful analysis of scientific articles, it has been concluded that magnolol is a promising agent supporting the conventional therapies with antidiabetic drugs in order to manage diabetes and diabetes-related diseases. Mechanisms of antidiabetes are still unclear for Magnolia constituents. Magnolia extracts are not used in antidiabetic clinical trials, though clinical trials have demonstrated that magnolia extract may be important medicines for treating a variety of conditions such as menopause, anxiety, and gingivitis.

5.6 Anticancer Properties

Evidence level: Preclinical (cell cultures and animal models); no controlled human clinical trials for isolated magnolol as an anticancer agent.

Numerous preclinical studies have established that magnolol exerts its effect on different types of human cancers such as those of lung, prostate, breast, gallbladder, colon, skin, and hepatocellular carcinoma. Numerous preclinical studies on magnolol have shown its cytotoxic potential against different cancers and other medical conditions. Through several molecular mechanisms, magnolol suppressed the pathogenesis and repressed the spread of cancer in vitro and in vivo.

Magnolol has garnered significant interest for its anti-cancer effects. Numerous studies conducted on cell lines and animal models have indicated a positive impact of administering drugs or semi-synthesized products derived from magnolol, including a decreased incidence of various cancers.

Magnolol could suppress cell migration and induced cell apoptosis via the inhibition of the NF-κB signaling pathway in human multiple myeloma cells. The overwhelming preponderance of anticancer evidence is in vitro or in animal xenograft models; translation to clinical oncology has not been established.

5.7 Antimicrobial Effects

Evidence level: In vitro and some animal data.

Magnolol was found to have good antibacterial activity against Bacillus subtilis, Staphylococcus aureus, and Mycobacterium smegmatis. Additionally, magnolol and honokiol were found to be moderately active against Candida albicans, Saccharomyces cerevisiae, Aspergillus niger, and strongly active against Trichophyton mentagrophytes, compared to amphotericin B.

Magnolol has antifungal properties and demonstrates anti-periodontal disease effects in animal models.

5.8 Bone Metabolism

Evidence level: Cell culture studies only.

In cell cultures, magnolol stimulates osteoblasts and inhibits osteoclasts, indicating potential for anti-osteoporosis treatment. No human or in vivo animal trials have established clinical relevance.

5.9 Hepatoprotective Effects

Evidence level: Animal model studies.

Alcohol-induced ALT and AST levels were significantly reduced by magnolol, while the antioxidant enzymes GSH-Px and SOD levels were significantly increased. Magnolol attenuated alcohol-induced pathologic damage such as decreasing hepatic cord swelling, hepatocyte necrosis, and inflammatory cell infiltration. These findings are from a mouse model of acute alcoholic liver disease.

5.10 Skin and Dermatological Applications

Evidence level: Animal model and cell culture studies.

Magnolia has been commonly included in two traditional Korean herbal medicines for atopic dermatitis treatment, and magnolol is the major constituent of Magnolia. It had not yet been explored in vivo whether magnolol is effective against atopic dermatitis, which prompted evaluation in a murine DNCB-induced atopic dermatitis model.

6. Pharmacokinetics and Bioavailability

The low water solubility, the low bioavailability, and the rapid metabolism of magnolol dramatically limit its clinical application.

The absorption half-life, elimination half-life, maximum concentration, and time to reach maximum concentration were found to be 0.63 h, 2.33 h, 0.16 µg/mL, and 1.12 h, respectively. This study indicated that the oral bioavailability of magnolol was 4.9%, suggesting poor water solubility and absorption in the gut.

Similar to other dietary polyphenols, magnolol and honokiol are subject to glucuronidation, and despite a relatively quick clearance, an interaction with pharmaceutical active principles or other herbal constituents cannot be excluded.

UGT1A7 and UGT1A9 have been selectively inhibited by magnolol with Ki values of 0.487 μM and 0.048 μM, respectively. Magnolol is thus considered an atypical substrate of UGT. This indicates that magnolol can show competitive activity with other drugs for interacting with UGT.

Due to the low water solubility and quick metabolism, magnolol has a low bioavailability and limits its applications in clinical development.

To address these limitations, investigators have developed formulation strategies. Drug carrier systems enhance the stability of the medication, improve pharmacokinetic parameters, and consequently increase bioavailability. Systems under investigation include binary mixed micelle systems, nanoparticles, and self-assembling lecithin-based mixed polymeric micelles.

7. Dosage Forms and Doses Reported in Research

The following doses are reported strictly as described in cited research sources; they do not represent clinical recommendations.

• Anxiolytic/sleep promotion (animal): Magnolol administered intraperitoneally at doses of 5 or 25 mg/kg significantly shortened sleep latency and increased NREM and REM sleep in mice.
• Anti-inflammatory (animal): Histopathological manifestations in DSS-treated mice were markedly improved after treatment with magnolol at 5–20 mg/kg.
• Safety assessment (subchronic, animal): A subchronic study performed according to OECD guidelines established a no-adverse-effect level for concentrated magnolia bark extract of greater than 240 mg/kg body weight per day.
• Cardiovascular (proposed adult daily oral): A daily dose of 120 mg of magnolol for a 60-kg adult is considered sufficient for cardiovascular protection, and such a dosage is considered applicable and safe based on available safety studies. This figure appears in a patent document and is not from a peer-reviewed clinical trial.
• Neurological (animal, oral): Oral application of M. officinalis ethanol extract at 2.5, 5, or 10 mg/kg doses improved Aβ1–42-induced memory impairments in transgenic mice.
• Antidiabetic (cell culture): HepG2 cells were incubated with magnolol at 4 µg/mL and oleic acid at 120 µM for 24 hours in one hepatic steatosis in vitro model.

No standardized or consensus clinical dosing regimen for isolated magnolol in humans has been established through randomized controlled trials.

8. Safety, Toxicology, and Drug Interactions

8.1 General Safety Profile

Magnolol is a small polyphenolic molecule with low toxicity that is isolated from the herb genus Magnolia.

In vitro and in vivo genotoxicity studies indicated that concentrated magnolia bark extract has no mutagenic and genotoxic potential, while a subchronic study performed according to OECD guidelines established a no-adverse-effect level for concentrated magnolia bark extract greater than 240 mg/kg body weight per day.

Intervention trials employing concentrated magnolia bark extract for up to one year did not report adverse effects. Over recent years, different food safety authorities evaluated magnolol and honokiol and considered them safe.

8.2 UGT-Mediated Drug Interactions

Magnolol can show competitive activity with other drugs for interacting with UGT. It has been demonstrated that magnolol in humans can inhibit the glucuronidation of propofol, which is considered the biomarker of UGT1A9 reaction. Thus, magnolol has been proposed to prolong anesthesia time.

It has been found that magnolol-mediated inhibition of propofol glucuronidation varies among species dramatically, including Bama pigs, cynomolgus macaques, mice, and rats. The clinical relevance of this interaction in humans taking oral supplements has not been fully quantified, but the potential for interaction with drugs metabolized by UGT1A9 and UGT1A7 warrants awareness.

Similar to other dietary polyphenols, magnolol and honokiol are subject to glucuronidation, and despite a relatively quick clearance, an interaction with pharmaceutical active principles or other herbal constituents cannot be excluded.

8.3 Contact Allergy

Magnolia officinalis bark extract has been identified as a contact allergen in certain "anti-ageing" cosmetics, as noted in contact dermatitis literature. This represents a route-specific (topical) safety concern distinct from oral supplementation.

8.4 Physicochemical and Formulation-Related Safety Considerations

The use of magnolol can be limited due to chemical instability. The stability of magnolol can be affected by hydrolytic and oxidizing conditions due to its biphenolic structure. This instability can affect both efficacy and the safety profile of degradation products in poorly formulated preparations.

8.5 Pregnancy and Special Populations

The published safety literature does not provide robust data on magnolol use in pregnancy, lactation, or pediatric populations. Food safety authorities have evaluated magnolol and honokiol and considered them safe in the context of adult supplementation, but these evaluations do not specifically address vulnerable populations.

9. Current Research Limitations and Evidence Gaps

Although magnolol and honokiol have various pharmacological effects, their clinical potential remains untapped. More research is needed to improve the bioavailability of magnolol and honokiol and perform experiments to examine their therapeutic potential in humans.

The low water solubility, the low bioavailability, and the rapid metabolism of magnolol dramatically limit its clinical application. Magnolol exemplifies a typical type IV molecule within the biopharmaceutical classification system, characterized by low solubility and low absorption. The development of suitable oral delivery systems that can reliably achieve pharmacologically active tissue concentrations in humans remains an active area of pharmaceutical research.

The body of preclinical literature is extensive, encompassing multiple cancer types, neurological conditions, metabolic disorders, and infectious disease models. However, translation from cell and animal studies to human clinical benefit has not been established for any of these indications through adequately powered, placebo-controlled randomized trials of isolated magnolol. Combination formula studies (e.g., with Banxia Houpo decoction or Saibokuto) have demonstrated some clinical activity, but these involve multiple bioactive constituents, making attribution to magnolol alone impossible.

References

• Lee, Y.-J. et al. "Magnolol: A multifunctional compound isolated from the Chinese medicinal plant Magnolia officinalis." ScienceDirect / Integrative Medicine Research (2011).
• Wang, C. et al. "Magnolol Alleviates Inflammatory Responses and Lipid Accumulation by AMP-Activated Protein Kinase-Dependent PPARα Activation." PubMed / Frontiers in Microbiology (2018).
• Zhang, Z. et al. "Insights on the Multifunctional Activities of Magnolol." BioMed Research International / PMC (2019).
• García-García, A. et al. "Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties." PMC / Molecules (2021).
• National Center for Biotechnology Information. "Magnolol, CID 72300." PubChem Compound Database, NIH.
• Wikipedia contributors. "Magnolol." Wikipedia, The Free Encyclopedia.
• Memorial Sloan Kettering Cancer Center. "Magnolia officinalis." Integrative Medicine monograph.
• ScienceDirect Topics. "Magnolia Officinalis — an overview." Pharmacology, Toxicology and Pharmaceutical Science.
• Margarucci, L. et al. "Chemical Proteomics-Guided Identification of a Novel Biological Target of the Bioactive Neolignan Magnolol." PMC / Frontiers in Chemistry (2019).
• Ranaware, A. M. et al. "Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer." PMC / International Journal of Molecular Sciences (2018).
• Yang, H. et al. "Magnolol attenuates the inflammation and enhances phagocytosis through the activation of MAPK, NF-κB signal pathways in vitro and in vivo." PubMed (2019).
• "The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms." PubMed (2022).
• "Role of magnolol in neuroprotection: cellular mechanisms, therapeutic potential and insights into safety and efficacy." ScienceDirect (2026).
• Lin, Y. et al. "Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update." Frontiers in Pharmacology (2021).
• Lin, Y. et al. "Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update." PMC / Frontiers in Pharmacology (2021).
• "Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the benzodiazepine site of GABA(A) receptor in mice." PubMed (2012).
• Sarrica, A. et al. "Safety and Toxicology of Magnolol and Honokiol." PubMed / Phytotherapy Research (2018).
• "Anti-Inflammatory and Antioxidant Properties of Carvacrol and Magnolol, in Periodontal Disease and Diabetes Mellitus." PMC / Nutrients (2021).
• "Depression and Its Phytopharmacotherapy — A Narrative Review." PMC (2023).
• "Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential." PMC (2025).
• Czyżewska, U. et al. "Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities — A Review." PMC / International Journal of Molecular Sciences (2021).
• "Cardiovascular protection of magnolol: cell-type specificity and dose-related effects." PMC / Journal of Biomedical Science (2012).
• "Anti-Arthritic Effects of Magnolol in Human Interleukin 1β-Stimulated Fibroblast-Like Synoviocytes and in a Rat Arthritis Model." PMC / PLOS ONE (2012).
• "Magnolol Prevents Acute Alcoholic Liver Damage by Activating PI3K/Nrf2/PPARγ and Inhibiting NLRP3 Signaling Pathway." PMC (2019).
• "Magnolol Reduces Atopic Dermatitis-like Symptoms in BALB/c Mice." PMC (2024).
• "Extracts of Magnolia Species-Induced Prevention of Diabetic Complications: A Brief Review." PMC (2016).
• "Magnolol and Luteolin Inhibition of α-Glucosidase Activity: Kinetics and Type of Interaction Detected by In Vitro and In Silico Studies." PMC (2022).
• Lee, J. et al. "Anti-inflammatory effects of magnolol and honokiol are mediated through inhibition of the downstream pathway of MEKK-1 in NF-kappaB activation signaling." PubMed / Planta Medica (2005).
• "Structural and Spectroscopic Properties of Magnolol and Honokiol — Experimental and Theoretical Studies." PMC (2025).
• "Honokiol and Magnolol as Multifunctional Antioxidative Molecules for Dermatologic Disorders." PMC / Molecules (2010).